These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 25075940)

  • 21. Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice.
    Farazi PA; Zeisberg M; Glickman J; Zhang Y; Kalluri R; DePinho RA
    Cancer Res; 2006 Jul; 66(13):6622-7. PubMed ID: 16818635
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Expression and significance of hepatitis B virus genes in human primary intrahepatic cholangiocarcinoma and its surrounding tissue].
    Wang W; Gu G; Hu M
    Zhonghua Zhong Liu Za Zhi; 1996 Mar; 18(2):127-30. PubMed ID: 9206046
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cancer-associated isocitrate dehydrogenase mutations.
    Yen KE; Schenkein DP
    Oncologist; 2012; 17(1):5-8. PubMed ID: 22234630
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases.
    Trauner M; Fickert P; Halilbasic E; Moustafa T
    Wien Med Wochenschr; 2008; 158(19-20):542-8. PubMed ID: 18998069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma.
    Graham RP; Barr Fritcher EG; Pestova E; Schulz J; Sitailo LA; Vasmatzis G; Murphy SJ; McWilliams RR; Hart SN; Halling KC; Roberts LR; Gores GJ; Couch FJ; Zhang L; Borad MJ; Kipp BR
    Hum Pathol; 2014 Aug; 45(8):1630-8. PubMed ID: 24837095
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dissecting the genetic susceptibility for cholangiocarcinoma in primary sclerosing cholangitis.
    Lazaridis KN
    Hepatology; 2008 Jan; 47(1):8-10. PubMed ID: 18161699
    [No Abstract]   [Full Text] [Related]  

  • 27. Treatment of recurrent intrahepatic cholangiocarcinoma (Br J Surg 2012; 99: 1711-1717).
    Fujita T
    Br J Surg; 2013 Mar; 100(4):573-4. PubMed ID: 23378206
    [No Abstract]   [Full Text] [Related]  

  • 28. Low expression of ARID1A correlates with poor prognosis in intrahepatic cholangiocarcinoma.
    Yang SZ; Wang AQ; Du J; Wang JT; Yu WW; Liu Q; Wu YF; Chen SG
    World J Gastroenterol; 2016 Jul; 22(25):5814-21. PubMed ID: 27433094
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined hepatocellular cholangiocarcinoma: Controversies to be addressed.
    Wang AQ; Zheng YC; Du J; Zhu CP; Huang HC; Wang SS; Wu LC; Wan XS; Zhang HH; Miao RY; Sang XT; Zhao HT
    World J Gastroenterol; 2016 May; 22(18):4459-65. PubMed ID: 27182157
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Author's reply: Treatment of recurrent intrahepatic cholangiocarcinoma (Br J Surg 2012; 99: 1711-1717).
    Boudjema K
    Br J Surg; 2013 Mar; 100(4):574. PubMed ID: 23378208
    [No Abstract]   [Full Text] [Related]  

  • 31. Response to Capmatinib in a MET Fusion-positive Cholangiocarcinoma.
    Turpin A; Descarpentries C; Grégoire V; Farchi O; Cortot AB; Jamme P
    Oncologist; 2023 Jan; 28(1):80-83. PubMed ID: 36434677
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Prognosis after resection of intrahepatic cholangiocarcinoma: clinical significance of KRAS mutations].
    Schneider MA; Büchler MW
    Chirurg; 2022 Mar; 93(3):306-307. PubMed ID: 35175401
    [No Abstract]   [Full Text] [Related]  

  • 33. Analysis of p53 mutations for a mutational signature in human intrahepatic cholangiocarcinoma.
    Khan SA; Taylor-Robinson SD; Carmichael PL; Habib N; Lemoine NR; Thomas HC
    Int J Oncol; 2006 May; 28(5):1269-77. PubMed ID: 16596244
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fibroblast growth factor receptor 2: a new potential therapeutic target for human cancer.
    Cheng C; Hu W; Liu LP; Li J
    Hum Pathol; 2015 Feb; 46(2):339-40. PubMed ID: 25466307
    [No Abstract]   [Full Text] [Related]  

  • 35. [Gallbladder and bile duct carcinoma. Biology and pathology].
    Tannapfel A; Wittekind C
    Internist (Berl); 2004 Jan; 45(1):33-41. PubMed ID: 14735242
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Primary bile duct carcinoma in histocompatibility antigen-identical twins.
    Christophi C; Nikfarjam M; Muralidharan V; Dudley F
    J Gastroenterol Hepatol; 2003 Apr; 18(4):469-72. PubMed ID: 12653905
    [No Abstract]   [Full Text] [Related]  

  • 37. Analysis of genetic changes in intrahepatic cholangiocarcinoma induced by thorotrast.
    Kamikawa T; Amenomori M; Itoh T; Momoi H; Hiai H; Machinami R; Ishikawa Y; Mori T; Shimahara Y; Yamaoka Y; Fukumoto M
    Radiat Res; 1999 Dec; 152(6 Suppl):S118-24. PubMed ID: 10564951
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EYA4 gene functions as a prognostic marker and inhibits the growth of intrahepatic cholangiocarcinoma.
    Hao XY; Cai JP; Liu X; Chen W; Hou X; Chen D; Lai JM; Liang LJ; Yin XY
    Chin J Cancer; 2016 Jul; 35(1):70. PubMed ID: 27469137
    [TBL] [Abstract][Full Text] [Related]  

  • 39. K-ras oncogene and p53 gene mutations in cholangiocarcinoma from Thai patients.
    Petmitr S; Pinlaor S; Thousungnoen A; Karalak A; Migasena P
    Southeast Asian J Trop Med Public Health; 1998 Mar; 29(1):71-5. PubMed ID: 9740272
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.
    Moeini A; Sia D; Zhang Z; Camprecios G; Stueck A; Dong H; Montal R; Torrens L; Martinez-Quetglas I; Fiel MI; Hao K; Villanueva A; Thung SN; Schwartz ME; Llovet JM
    J Hepatol; 2017 May; 66(5):952-961. PubMed ID: 28126467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.